Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimme Hyrich

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Best Practice & Research. Clinical Rheumatology|August 21, 2019
Malignancy and rheumatoid arthritis: Epidemiology, risk factors and managementDiederik De Cock, Kimme Hyrich
Arthritis Research & Therapy|December 2, 2016
What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Jenny Humphreys, Kimme Hyrich, Deborah Symmons
Current Opinion in Rheumatology|February 22, 2019
Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?Meghna Jani, Anne Barton, Kimme Hyrich
Arthritis Care & Research|April 21, 2015
Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and RegistersHelga Radner, William Dixon, Kimme Hyrich, et al.
Best Practice & Research. Clinical Rheumatology|December 12, 2018
Update on the epidemiology, risk factors and disease outcomes of Juvenile idiopathic arthritisJason Palman, Stephanie Shoop-Worrall, Kimme Hyrich, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 8, 2024
Genetically Proxied Interleukin-13 Inhibition Is Associated With Risk of Psoriatic Disease: A Mendelian Randomization StudySizheng Steven Zhao, Kimme Hyrich, Zenas Yiu, et al.
Journal of Biopharmaceutical Statistics|February 27, 2013
A threshold hazard model for estimating serious infection risk following anti-tumor necrosis factor therapy in rheumatoid arthritis patientsBo Fu, Mark Lunt, James Galloway, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 17, 2021
Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid ArthritisThomas R P Taylor, James Galloway, Rebecca Davies, et al.
Rheumatology (Oxford, England)|November 13, 2019
Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RAPhilip D H Hamann, John D Pauling, Neil McHugh, et al.
Rheumatology (Oxford, England)|June 4, 2019
Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patientsPhilip D H Hamann, John D Pauling, Neil McHugh, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Best Practice & Research. Clinical Rheumatology|August 21, 2019
Malignancy and rheumatoid arthritis: Epidemiology, risk factors and managementDiederik De Cock, Kimme Hyrich
Arthritis Research & Therapy|December 2, 2016
What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Jenny Humphreys, Kimme Hyrich, Deborah Symmons
Current Opinion in Rheumatology|February 22, 2019
Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?Meghna Jani, Anne Barton, Kimme Hyrich
Arthritis Care & Research|April 21, 2015
Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and RegistersHelga Radner, William Dixon, Kimme Hyrich, et al.
Best Practice & Research. Clinical Rheumatology|December 12, 2018
Update on the epidemiology, risk factors and disease outcomes of Juvenile idiopathic arthritisJason Palman, Stephanie Shoop-Worrall, Kimme Hyrich, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 8, 2024
Genetically Proxied Interleukin-13 Inhibition Is Associated With Risk of Psoriatic Disease: A Mendelian Randomization StudySizheng Steven Zhao, Kimme Hyrich, Zenas Yiu, et al.
Journal of Biopharmaceutical Statistics|February 27, 2013
A threshold hazard model for estimating serious infection risk following anti-tumor necrosis factor therapy in rheumatoid arthritis patientsBo Fu, Mark Lunt, James Galloway, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|April 17, 2021
Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid ArthritisThomas R P Taylor, James Galloway, Rebecca Davies, et al.
Rheumatology (Oxford, England)|November 13, 2019
Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RAPhilip D H Hamann, John D Pauling, Neil McHugh, et al.
Rheumatology (Oxford, England)|June 4, 2019
Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patientsPhilip D H Hamann, John D Pauling, Neil McHugh, et al.
Pageof 5